AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |
Back to Blog
No reflow phenomenon12/18/2023 Adenosine and verapamil for no-reflow during primary percutaneous coronary intervention in people with acute myocardial infarction. Short-Term Effects of Verapamil and Diltiazem in the Treatment of No Reflow Phenomenon: A Meta-Analysis of Randomized Controlled Trials. Nicardipine and adenosine "flush cocktail" to prevent no-reflow during rotational atherectomy. Myocardial 'no-reflow'-diagnosis, pathophysiology and treatment. Wong DT, Puri R, Richardson JD, Worthley MI, Worthley SG. No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention. Resnic FS, Wainstein M, Lee MK, Behrendt D, Wainstein RV, Ohno-Machado L, et al. Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. Morishima I, Sone T, Okumura K, Tsuboi H, Kondo J, Mukawa H, et al. Predictors and long-term prognosis of angiographic slow/no-reflow phenomenon during emergency percutaneous coronary intervention for ST-elevated acute myocardial infarction. Features and outcome of no-reflow after percutaneous coronary intervention. Incidence and outcomes of no-reflow phenomenon during percutaneous coronary intervention among patients with acute myocardial infarction. Harrison RW, Aggarwal A, Ou FS, Klein LW, Rumsfeld JS, Roe MT, et al. Niccoli G, Burzotta F, Galiuto L, Crea F. The no-reflow phenomenon in the young and in the elderly. The association of serum uric acid levels on coronary flow in patients with STEMI undergoing primary PCI. 2017 8(45):79767-74.ĥ.Ěkpek M, Kaya MG, Uyarel H, Yarlioglues M, Kalay N, Gunebakmaz O, et al. Influence of angiographic spontaneous coronary reperfusion on long-term prognosis in patients with ST-segment elevation myocardial infarction. Li X, Li B, Gao J, Wang Y, Xue S, Jiang D, et al. The effect of statins on the no-reflow phenomenon: an observational study in patients with hyperglycemia before primary angioplasty. Zhao JL, Yang YJ, Pei WD, Sun YH, Chen JL. Microvascular obstruction and the no-reflow phenomenon after percutaneous coronary intervention. Jaffe R, Charron T, Puley G, Dick A, Strauss BH. Age of more than 62.5 years and serum creatinine level of more than 0.89 mg/dL can optimally predict the no reflow phenomena.Ĭonclusions: According to our results, it seems that female gender, older ages, DM, multi-vessel involvement, delayed reperfusion, and increased NLR can predict the risk of no-reflow after primary PCI in the setting of Acute Myocardial Infarction.ġ.ĝurante A, Latib A, Pizzetti G, Colombo A, Camici PG. TFC had negative significant correlation with male gender, and positive significant correlation with age, diabetes mellitus, hs-CRP level, WBC count, and NLR. Symptom-to-procedure time, door-to-procedure time, serum creatinine level, hs-CRP level, and Neutrophil to Lymphocyte Ratio (NLR) were significantly higher among group 2. Results: Patients with a mean age of 56.41 ± 11.8 years were divided into two groups depending on the TIMI score (Group 1 or Normal flow and Group 2 or No-reflow). The correlation of no-reflow phenomenon with demographic, biochemical and anatomical factors was analyzed. Also, the Thrombolysis in Myocardial Infarction (TIMI) grade and TIMI frame count (TFC) was measured. Demographic factors, as well as biochemistry test results were obtained. Methods: We included 306 patients (193 male) with acute ST-elevation myocardial infarction (STEMI) who undergone primary PCI in our center. In this study, we have evaluated the correlation of no-reflow phenomenon with demographic, biochemical and anatomical factors. Background:The coronary no-reflow phenomenon is an adverse complication of percutaneous coronary interventions (PCI) which significantly worsens the outcome and survival.
0 Comments
Read More
Leave a Reply. |